Uses
O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice[1].
Definition
ChEBI: N-[6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c][1]benzopyran-3-yl]hex-4-ynyl]methanesulfonamide is a 1-benzopyran.
in vivo
O-2050 (1, 3, 10, 30 mg/kg; ip; pretreatment 30 mins) produces significant and dose-dependent decreases in food intake in mice. O-2050 (10, 30 mg/kg) significantly causes locomotor stimulation[1].
IC 50
CB1: 2.5 nM (Ki); CB2: 0.2 nM (Ki)
References
[1] Jenny L Wiley, et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. DOI:
10.1016/j.ejphar.2010.10.085